As part of the NICE’s single technology appraisal process, this assessment aims at critically reviewing the manufacturer’s submission related to the evidence for the clinical and cost-effectiveness of radium-223 dichloride (trade name Xofigo) for the treatment of metastatic castration resistant prostate cancer. The submission focuses on an international, multicentre, double-blind phase three randomised controlled trial (RCT) sponsored by the manufacturer. Evidence from a smaller phase-two, international multicentre, double-blind RCT are presented in a supportive role.
Craig Ramsay; email@example.com
Completed; for further information see: http://www.nets.nihr.ac.uk/projects/hta/125701